VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Thursday, January 8, 2026
Stock Comparison
Brookfield Asset Management Ltd. vs Gilead Sciences, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Brookfield Asset Management Ltd.
BAM · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Brookfield Asset Management Ltd.'s moat claims, evidence, and risks.
View BAM analysisGilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisComparison highlights
- Moat score gap: Brookfield Asset Management Ltd. leads (75 / 100 vs 74 / 100 for Gilead Sciences, Inc.).
- Segment focus: Brookfield Asset Management Ltd. has 5 segments (30.3% in Credit); Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
- Moat breadth: Brookfield Asset Management Ltd. has 4 moat types across 2 domains; Gilead Sciences, Inc. has 8 across 3.
Primary market context
Brookfield Asset Management Ltd.
Credit
Private credit, opportunistic credit, and multi-strategy credit asset management
Global
Institutional investors, insurance accounts, and private wealth investors
Alternative credit manager / asset manager
30.3%
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Side-by-side metrics
Moat coverage
Shared moat types
Brookfield Asset Management Ltd. strengths
Gilead Sciences, Inc. strengths
Segment mix
Brookfield Asset Management Ltd. segments
Full profile >Renewable Power and Transition
Oligopoly
Infrastructure
Oligopoly
Real Estate
Oligopoly
Private Equity
Oligopoly
Credit
Oligopoly
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.